Cite

    Mora, J. et al. (2019). Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients. Pediatric blood & cancer. 66 (6), p. n/a. [Online].